Golimumab as rescue therapy for refractory immune-mediated uveitis: A three-center experience

29Citations
Citations of this article
24Readers
Mendeley users who have this article in their library.

Abstract

Objective. To evaluate, in three Spanish tertiary referral centres, the short-term safety and efficacy of golimumab (GLM) for treatment of immune-mediated uveitis resistant to previous immunosuppressive therapy. Methods. Nonrandomized retrospective interventional case series. Thirteen patients with different types of uveitis that were resistant to treatment with at least 2 previous immunosuppressors were included in this study. All included patients were treated with GLM (50 mg every four weeks) during at least 6 months. Clinical evaluation and treatment-related side effects were assessed at least four times in all included patients. Results. Eight men and 5 women (22 affected eyes) with a median age of 30 years (range 20-38) and active immune-mediated uveitides were studied. GLM was used in combination with conventional immunosuppressors in 7 patients (53.8%). GLM therapy achieved complete control of inflammation in 12/13 patients (92.3%) after six months of treatment. There was a statistically significant improvement in mean BCVA (0.60 versus 0.68, P = 0.009) and mean 1 mm central retinal thickness (317 versus 261.2 , P = 0.05) at the six-month endpoint when compared to basal values. No major systemic adverse effects associated with GLM therapy were observed. Conclusions. GLM is a new and promising therapeutic option for patients with severe and refractory uveitis. © 2014 Miguel Cordero-Coma et al.

Cite

CITATION STYLE

APA

Cordero-Coma, M., Calvo-Río, V., Adán, A., Blanco, R., Álvarez-Castro, C., Mesquida, M., … Ruíz De Morales, J. G. (2014). Golimumab as rescue therapy for refractory immune-mediated uveitis: A three-center experience. Mediators of Inflammation, 2014. https://doi.org/10.1155/2014/717598

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free